Research & Literature

Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.

Sölétormos G, Duffy MJ, Othman Abu Hassan S, et al.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2016; (26(1)):43-51 doi:10.1097/IGC.0000000000000586.

Ovarian Cancer, the Revised FIGO Staging System, and the Role of Imaging.

Javadi S, Ganeshan DM, Qayyum A, et al.

AJR. American journal of roentgenology 2016; (206(6)):1351-60 doi:10.2214/AJR.15.15199.

The revised 2014 FIGO staging system for epithelial ovarian cancer: Is a subclassification into FIGO stage IVA and IVB justified?

Ataseven B, Harter P, Grimm C, et al.

Gynecologic oncology 2016; (142(2)):243-7.

Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses.

Terlikowska KM, Dobrzycka B, Witkowska AM, et al.

Journal of ovarian research 2016; (9(1)):43 doi:10.1186/s13048-016-0254-7.

Epidemiological overview, advances in diagnosis, prevention, treatment and management of epithelial ovarian cancer in Mexico.

Gallardo-Rincón D, Espinosa-Romero R, Muñoz WR, et al.

Salud publica de Mexico 2016; (58(2)):302-8.

Correlation of pre-operative CT findings with surgical & histological tumor dissemination patterns at cytoreduction for primary advanced and relapsed epithelial ovarian cancer: A retrospective evaluation.

Nasser S, Lazaridis A, Evangelou M, et al.

Gynecologic oncology 2016; (143(2)):264-269 doi:10.1016/j.ygyno.2016.08.322.

The disparate origins of ovarian cancers: pathogenesis and prevention strategies.

Karnezis AN, Cho KR, Gilks CB, et al.

Nature reviews. Cancer 2017; (17(1)):65-74 doi:10.1038/nrc.2016.113.

High grade serous ovarian carcinomas originate in the fallopian tube.

Labidi-Galy SI, Papp E, Hallberg D, et al.

Nature communications 2017; (8(1)):1093 doi:10.1038/s41467-017-00962-1.

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.

van Driel WJ, Koole SN, Sikorska K, et al.

The New England journal of medicine 2018; (378(3)):230-240 doi:10.1056/NEJMoa1708618.

Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision.

Lewis KE, Lu KH, Klimczak AM, Mok SC

Cancers 2018; (10(2)) doi:10.3390/cancers10020057.

Laparoscopic Assessment to Determine the Likelihood of Achieving Optimal Cytoreduction in Patients Undergoing Primary Debulking Surgery for Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Andikyan V, Kim A, Gretz HF, et al.

American journal of clinical oncology 2018; (41(10)):938-942 doi:10.1097/COC.0000000000000413.

Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage.

Peres LC, Cushing-Haugen KL, Köbel M, et al.

Journal of the National Cancer Institute 2019; (111(1)):60-68 doi:10.1093/jnci/djy071.

Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors.

Chen F, Shen J, Wang J, et al.

Cancer management and research 2018; (10()):1313-1318 doi:10.2147/CMAR.S155693.

Pre-operative assessment of intra-abdominal disease spread in epithelial ovarian cancer: a comparative study between ultrasound and computed tomography.

Alcázar JL, Caparros M, Arraiza M, et al.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2019; (29(2)):227-233 doi:10.1136/ijgc-2018-000066.

Mucinous Neoplasms of the Ovary: Radiologic-Pathologic Correlation.

Marko J, Marko KI, Pachigolla SL, et al.

Radiographics : a review publication of the Radiological Society of North America, Inc 2019; (39(4)):982-997 doi:10.1148/rg.2019180221.

Ovarian Cancer Previvors: How to manage these patients?

Carvalho JP, Baracat EC, Carvalho FM

Clinics (Sao Paulo, Brazil) 2019; (74()):e1343 doi:10.6061/clinics/2019/e1343.

Ovarian cancer screening in the general population.

Mathis J, Jellouli MA, Sabiani L, et al.

Hormone molecular biology and clinical investigation 2019; (41(3)) doi:10.1515/hmbci-2019-0038.

Low-grade serous ovarian carcinoma: A comprehensive literature review.

Goulding EA, Simcock B, McLachlan J, et al.

The Australian & New Zealand journal of obstetrics & gynaecology 2020; (60(1)):27-33 doi:10.1111/ajo.13105.

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

Ray-Coquard I, Pautier P, Pignata S, et al.

The New England journal of medicine 2019; (381(25)):2416-2428 doi:10.1056/NEJMoa1911361.

Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.

Eoh KJ, Kim HM, Lee JY, et al.

BMC cancer 2020; (20(1)):204 doi:10.1186/s12885-020-6693-y.

Ovarian cancer screening: Current status and future directions.

Nash Z, Menon U

Best practice & research. Clinical obstetrics & gynaecology 2020; (65()):32-45 doi:10.1016/j.bpobgyn.2020.02.010.

Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy.

Lyons YA, Reyes HD, McDonald ME, et al.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2020; (30(6)):845-852 doi:10.1136/ijgc-2019-001124.

The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers.

Chelariu-Raicu A, Zibetti Dal Molin G, Coleman RL

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2020; (30(10)):1608-1618 doi:10.1136/ijgc-2020-001789.

DNA Methylation Profiling of Premalignant Lesions as a Path to Ovarian Cancer Early Detection.

Ishak CA, De Carvalho DD

Clinical cancer research : an official journal of the American Association for Cancer Research 2020; (26(23)):6083-6085 doi:10.1158/1078-0432.CCR-20-3331.

Stage III disease of ovarian, tubal and peritoneal cancers can be accurately diagnosed with pre-operative CT. Japan Clinical Oncology Group Study JCOG0602.

Onda T, Tanaka YO, Kitai S, et al.

Japanese journal of clinical oncology 2021; (51(2)):205-212 doi:10.1093/jjco/hyaa145.

HE4 might be a more useful tumor biomarker to detect malignancy in patients with ovarian endometrioma when malignancy is suspected.

Rius M, Fusté P, Ros C, et al.

The Journal of international medical research 2021; (49(9)):3000605211047701 doi:10.1177/03000605211047701.

Next steps in the early detection of ovarian cancer.

Bast RC, Han CY, Lu Z, Lu KH

Communications medicine 2021; (1()) doi:10.1038/s43856-021-00037-9.

The Performance of HE4 Alone and in Combination with CA125 for the Detection of Ovarian Cancer in an Enriched Primary Care Population.

Barr CE, Funston G, Jeevan D, et al.

Cancers 2022; (14(9)) doi:10.3390/cancers14092124.

Incidence and Survival Rates for Female Malignant Germ Cell Tumors: An Institutional Review.

Saeed Usmani A, Yasin I, Asif RB, et al.

Cureus 2022; (14(4)):e24497 doi:10.7759/cureus.24497.

The proteome of clear cell ovarian carcinoma.

Ji JX, Cochrane DR, Negri GL, et al.

The Journal of pathology 2022; (258(4)):325-338 doi:10.1002/path.6006.

Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer.

Elsea D, Fan L, Mihai A, et al.

PharmacoEconomics - open 2022; (6(6)):811-822 doi:10.1007/s41669-022-00338-2.

Molecular Biomarkers for the Early Detection of Ovarian Cancer.

Zhang R, Siu MKY, Ngan HYS, Chan KKL

International journal of molecular sciences 2022; (23(19)) doi:10.3390/ijms231912041.

Role of Neoadjuvant Chemotherapy in Ovarian Serous Cancer Followed by Debulking.

Chauhan S, Shrivastava D, Dhande R, Deo A

Cureus 2022; (14(9)):e28909 doi:10.7759/cureus.28909.

Evaluation of external validity of the OVHIPEC-1 trial in a real-world population.

van Stein RM, Sikorska K, van der Aa MA, et al.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2023; (161(2)):640-648 doi:10.1002/ijgo.14618.

Neoadjuvant Chemotherapy Versus Primary Debulking Surgery in FIGO Stage III and IV Epithelial Ovarian, Tubal or Peritoneal Cancer: A Systematic Review and Meta-Analysis.

Tzanis AA, Iavazzo C, Hadjivasilis A, et al.

Oncology reviews 2022; (16()):10605 doi:10.3389/or.2022.10605.

PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy.

Chelariu-Raicu A, Trillsch F, Burges A, et al.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2023; (33(5)):812-822 doi:10.1136/ijgc-2022-003990.

Frequency of serous tubal intraepithelial carcinoma (STIC) in patients with high grade serous ovarian cancer.

Byun JM, Cho HJ, Lee DS, et al.

Taiwanese journal of obstetrics & gynecology 2023; (62(1)):107-111 doi:10.1016/j.tjog.2022.09.006.

Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis.

Li Y

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology 2023; (43(1)):2171282 doi:10.1080/01443615.2023.2171282.

Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study.

Morgan RD, Clamp AR, Barnes BM, et al.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2023; (33(8)):1253-1259 doi:10.1136/ijgc-2022-004211.

Patient-Initiated Follow-Up in Ovarian Cancer.

Luk HM, Ngu SF, Lau LSK, et al.

Current oncology (Toronto, Ont.) 2023; (30(4)):3627-3636 doi:10.3390/curroncol30040276.

Cost-Effectiveness Analysis of Biomarker Testing to Guide First-Line PARP Inhibitor Maintenance for Patients with Advanced Ovarian Cancer After Response to First-Line Platinum Chemotherapy in the USA.

Elsea D, Muston D, Fan L, et al.

Targeted oncology 2023; (18(4)):531-541 doi:10.1007/s11523-023-00966-6.

Molecular Status of BRAF Mutation in Epithelial Ovarian Cancer: An Analysis of 57 Cases in the Northeast of Iran.

Jafarian A, Jafaripour M, Gharib M, et al.

Iranian journal of pathology 2023; (18(2)):134-139 doi:10.30699/IJP.2023.554750.2907.

Plasma cell-free DNA methylation analysis for ovarian cancer detection: Analysis of samples from a case-control study and an ovarian cancer screening trial.

Herzog C, Jones A, Evans I, et al.

International journal of cancer 2024; (154(4)):679-691 doi:10.1002/ijc.34757.

Developments in Genetics: Better Management of Ovarian Cancer Patients.

Maioru OV, Radoi VE, Coman MC, et al.

International journal of molecular sciences 2023; (24(21)) doi:10.3390/ijms242115987.

How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature.

Arcieri M, Tius V, Andreetta C, et al.

Frontiers in oncology 2024; (14()):1335196 doi:10.3389/fonc.2024.1335196.

The unique metabolome of clear cell ovarian carcinoma.

Ji JX, Hoang LN, Cochrane DR, et al.

The Journal of pathology 2024; (264(2)):160-173 doi:10.1002/path.6329.

Efficacy and safety of PARP inhibitor maintenance therapy for ovarian cancer: a meta-analysis and trial sequential analysis of randomized controlled trials.

Sun G, Liu Y

Frontiers in pharmacology 2024; (15()):1460285 doi:10.3389/fphar.2024.1460285.

Stage migration and survival outcomes in patients with cervical cancer at Stage IIIC according to the 2018 FIGO staging system: a systematic review and meta-analysis.

Han L, Chen Y, Zheng A, et al.

Frontiers in oncology 2024; (14()):1460543 doi:10.3389/fonc.2024.1460543.

Pure Leydig cell tumor of the ovary: a rare presentation of a rare entity in a pregnant patient.

Rjoop A, Almohtaseb A, Al Aruri DO, et al.

Future science OA 2024; (10(1)):2424144 doi:10.1080/20565623.2024.2424144.

Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced epithelial ovarian cancer.

Shawky M, Choudhary C, Coleridge SL, et al.

The Cochrane database of systematic reviews 2025; (2()):CD005343 doi:10.1002/14651858.CD005343.pub7.

The Role of CA-125 in the Management of Ovarian Cancer: A Systematic Review.

Momenimovahed Z, Mazidimoradi A, Allahqoli L, Salehiniya H

Cancer reports (Hoboken, N.J.) 2025; (8(3)):e70142 doi:10.1002/cnr2.70142.

Expression of Programmed Cell Death Ligand 1 and Mismatch Repair Status in Ovarian Carcinomas.

Hariprasad M, Rao M, Elhence PA, et al.

Journal of mid-life health 2025; (16(3)):309-314 doi:10.4103/jmh.jmh_102_25.

Effectiveness and safety of PARP inhibitors in breast cancer: An umbrella review of systematic reviews and meta-analyses.

Tzang CC, Wu HW, Luo CA, et al.

Critical reviews in oncology/hematology 2025; (217()):105048 doi:10.1016/j.critrevonc.2025.105048.

Targeting Ovarian Neoplasms: Subtypes and Therapeutic Options.

Hong SY, Cho A, Chae CS, You HJ

Medicina (Kaunas, Lithuania) 2025; (61(12)) doi:10.3390/medicina61122246.